Final answer:
The FDA has indicated that insulin glargine-yfgn (Semglee) is the only biosimilar product interchangeable with its reference product, Lantus, a long-acting insulin for diabetes.
Step-by-step explanation:
The Food and Drug Administration (FDA) has established a pathway for the approval of biosimilar products, which are highly similar to an already approved biological product and have no clinically meaningful differences in terms of safety and effectiveness. According to the reference provided, the FDA has indicated that a biosimilar product can be considered interchangeable with its reference product, which means that it can be expected to produce the same clinical result in any given patient and that if the product is administered more than once to an individual, the risk in terms of safety or diminished efficacy of alternating or switching between the biosimilar and the reference product is not greater than the risk of using the reference product without such alternation or switch.
As of my knowledge cutoff date in 2023, the only biosimilar product that has received an 'interchangeable' designation by the FDA is insulin glargine-yfgn (brand name Semglee), which is interchangeable with its reference product, Lantus, a long-acting insulin used to control high blood sugar in adults with diabetes mellitus.